Polaris Pharmaceuticals
Bharat C. has a diverse work experience in the pharmaceutical industry. Bharat began their career at Western Illinois University as a Teaching Assistant, where they supervised and mentored students and assisted in designing new organic analogs. Bharat then worked at Aurex Laboratories LLC as a Junior QC Associate, where they created and reviewed technical documentation and assisted in regulatory filings for drug approvals. Bharat then joined Navinta LLC as a Chemist, where they performed routine testing on R&D samples and gained experience in publishing original applications, supplements, amendments, and annual reports. Bharat later joined Gilead Sciences as a Sr. Regulatory Operations Consultant, leading the publishing of regulatory submissions for original applications, amendments, supplements, and various reports. Bharat also prepared and submitted submissions types for different health agencies. Currently, Bharat is working at Polaris Pharmaceuticals as the Manager of Regulatory Operations, where they are responsible for preparing and managing regulatory submissions for various applications and documents and submitting them to the FDA and international regulatory agencies.
Bharat C. has a Bachelor's degree in Pharmacy from Kakatiya University's University College of Pharmaceutical Sciences. Bharat then pursued a Master's degree in Pharmaceutical Sciences from Jawaharlal Nehru Technological University. Following that, they completed another Master's degree in Chemistry from Western Illinois University.
This person is not in any teams
Polaris Pharmaceuticals
Polaris Group, a privately held multinational biopharmaceutical drug company, specializes in the research and development of protein drugs to treat cancer and other debilitating diseases in humans. Polaris' lead project is ADI-PEG 20, a biotherapeutic agent that is in advanced clinical development for the treatment of hepatocellular carcinoma and metastatic melanoma. Polaris is collaborating with EnzymeRx in the development of Uricase-PEG 20 for the treatment of gout, tumor lysis syndrome, and other diseases related to hyperuricemia. Polaris is also researching and developing other biotherapeutic agents and has a small molecule drug program. The latter utilizes a rational structure-based approach for the design of novel compounds that inhibit the biological function of cancer-related protein targets.